Vaxcyte Shares Jump 57 Percent on Trial Success
Vaxcyte shares surged after its experimental pneumococcal vaccine met primary goals in a late stage study. The vaccine showed strong immune responses compared to rival treatments. The company plans to apply for US approval in 2028.
Xurve View
Insights:
Xurve View
VAXCYTE INC shares rose 57% in morning trading after its experimental pneumococcal vaccine matched rival products in a late-stage trial. The study evaluated the VAX-31 vaccine against established therapies in older adults. The successful trial positions the company to challenge established market leaders in the adult vaccine sector.
